ID   BL-2
AC   CVCL_1966
SY   BL2; BL 2; BL 02; BL02; BL 002; IARC/BL2; IARC/BL 02; IARC-BL2; IARC BL2; IARC-BL-2; IARC BL 2
DR   BTO; BTO:0002748
DR   EFO; EFO_0005475
DR   BioSample; SAMN03473506
DR   Cosmic; 931095
DR   Cosmic; 2814531
DR   DepMap; ACH-001449
DR   DSMZ; ACC-625
DR   DSMZCellDive; ACC-625
DR   Lonza; 110
DR   Wikidata; Q54797121
RX   PubMed=1356511;
RX   PubMed=1915267;
RX   PubMed=2052620;
RX   PubMed=2825176;
RX   PubMed=3027441;
RX   PubMed=3035497;
RX   PubMed=3004968;
RX   PubMed=3026973;
RX   PubMed=3905596;
RX   PubMed=3934070;
RX   PubMed=6592381;
RX   PubMed=6806672;
RX   PubMed=6825067;
RX   PubMed=8896424;
RX   PubMed=9473234;
RX   PubMed=11793449;
RX   PubMed=22885699;
RX   PubMed=24590883;
RX   PubMed=25960936;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   From: International Agency of Research on Cancer (IARC); Lyon; France.
CC   Population: Caucasian; French.
CC   Virology: EBV-negative.
CC   Doubling time: ~24 hours (DSMZ=ACC-625).
CC   HLA typing: A*24:02,24:02; B*08:01,39:06; C*07:02,07:02; DQA1*01:01,05:01; DQB1*02:01,06:02; DRB1*03:01,14:01 (PubMed=25960936).
CC   Sequence variation: Gene fusion; HGNC; 5853; IGL + HGNC; 7553; MYC; Name(s)=MYC-IGL (PubMed=6806672).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): DSMZ=ACC-625
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 11,12
ST   D16S539: 12
ST   D18S51: 12,21
ST   D19S433: 12,15
ST   D21S11: 29,31
ST   D2S1338: 20
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 8,12
ST   D8S1179: 13,15
ST   FGA: 21,23
ST   Penta D: 9,15
ST   Penta E: 12
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 15,16
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_IV28 ! IARC-304
SX   Male
AG   7Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 30
//
RX   PubMed=1356511; DOI=10.1182/blood.V80.7.1781.1781;
RA   Gaidano G., Hauptschein R.S., Parsa N.Z., Offit K., Rao P.H.,
RA   Lenoir G.M., Knowles D.M., Chaganti R.S.K., Dalla-Favera R.;
RT   "Deletions involving two distinct regions of 6q in B-cell non-Hodgkin
RT   lymphoma.";
RL   Blood 80:1781-1787(1992).
//
RX   PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x;
RA   Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
//
RX   PubMed=2052620; DOI=10.1073/pnas.88.12.5413;
RA   Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A.,
RA   Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.;
RT   "p53 mutations in human lymphoid malignancies: association with
RT   Burkitt lymphoma and chronic lymphocytic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991).
//
RX   PubMed=2825176; DOI=10.1073/pnas.84.22.8060;
RA   Calender A., Billaud M., Aubry J.-P., Banchereau J., Vuillaume M.,
RA   Lenoir G.M.;
RT   "Epstein-Barr virus (EBV) induces expression of B-cell activation
RT   markers on in vitro infection of EBV-negative B-lymphoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:8060-8064(1987).
//
RX   PubMed=3027441; DOI=10.1093/jnci/78.2.235;
RA   Cohen J.H.M., Revillard J.-P., Magaud J.-P., Lenoir G.M., Vuillaume M.,
RA   Manel A.-M., Vincent C., Bryon P.-A.;
RT   "B-cell maturation stages of Burkitt's lymphoma cell lines according
RT   to Epstein-Barr virus status and type of chromosome translocation.";
RL   J. Natl. Cancer Inst. 78:235-242(1987).
//
RX   PubMed=3035497; DOI=10.1093/nar/15.11.4553;
RA   Szajnert M.-F., Saule S., Bornkamm G.-W., Wajcman H., Lenoir G.M.,
RA   Kaplan J.-C.;
RT   "Clustered somatic mutations in and around first exon of
RT   non-rearranged c-myc in Burkitt lymphoma with t(8;22) translocation.";
RL   Nucleic Acids Res. 15:4553-4565(1987).
//
RX   PubMed=3004968; DOI=10.1002/j.1460-2075.1985.tb04140.x;
RA   Eick D., Piechaczyk M., Henglein B., Blanchard J.-M., Traub B.,
RA   Kofler E., Wiest S., Lenoir G.M., Bornkamm G.-W.;
RT   "Aberrant c-myc RNAs of Burkitt's lymphoma cells have longer
RT   half-lives.";
RL   EMBO J. 4:3717-3725(1985).
//
RX   PubMed=3026973; DOI=10.1002/ijc.2910390215;
RA   Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.;
RT   "Expression of B-cell-specific markers in different Burkitt lymphoma
RT   subgroups.";
RL   Int. J. Cancer 39:211-218(1987).
//
RX   PubMed=3905596;
RA   Favrot M.-C., Philip I., Philip T., Cabrillat H., Pinatel C.,
RA   Dore J.-F., Lenoir G.M.;
RT   "Immunophenotypic classification of 28 Burkitt cell lines with
RT   monoclonal antibodies and reagent selection for bone-marrow purging.";
RL   IARC Sci. Publ. 60:447-452(1985).
//
RX   PubMed=3934070;
RA   Lenoir G.M., Vuillaume M., Bonnardel C.;
RT   "The use of lymphomatous and lymphoblastoid cell lines in the study of
RT   Burkitt's lymphoma.";
RL   IARC Sci. Publ. 60:309-318(1985).
//
RX   PubMed=6592381; DOI=10.1093/jnci/73.4.841;
RA   Favrot M.-C., Philip I., Philip T., Portoukalian J., Dore J.-F.,
RA   Lenoir G.M.;
RT   "Distinct reactivity of Burkitt's lymphoma cell lines with eight
RT   monoclonal antibodies correlated with the ethnic origin.";
RL   J. Natl. Cancer Inst. 73:841-847(1984).
//
RX   PubMed=6806672; DOI=10.1038/298474a0;
RA   Lenoir G.M., Preud'homme J.-L., Bernheim A., Berger R.;
RT   "Correlation between immunoglobulin light chain expression and variant
RT   translocation in Burkitt's lymphoma.";
RL   Nature 298:474-476(1982).
//
RX   PubMed=6825067; DOI=10.1016/0165-4608(83)90138-3;
RA   Bernheim A., Berger R., Lenoir G.M.;
RT   "Cytogenetic studies on Burkitt's lymphoma cell lines.";
RL   Cancer Genet. Cytogenet. 8:223-229(1983).
//
RX   PubMed=8896424; DOI=10.1182/blood.V88.9.3562.bloodjournal8893562;
RA   Chapman C.J., Zhou J.X., Gregory C.D., Rickinson A.B., Stevenson F.K.;
RT   "VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic
RT   hypermutation, intraclonal heterogeneity, and a role for antigen
RT   selection.";
RL   Blood 88:3562-3568(1996).
//
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
//
RX   PubMed=11793449; DOI=10.1002/gcc.10022;
RA   Sobol H., Benziane A., Kerangueven F., Yin L., Noguchi T., Pauly S.,
RA   Eisinger F., Longy M., Romeo G., Lenoir G.M., Birnbaum D.;
RT   "Genome-wide search for loss of heterozygosity in Burkitt lymphoma
RT   cell lines.";
RL   Genes Chromosomes Cancer 33:217-224(2002).
//
RX   PubMed=22885699; DOI=10.1038/nature11378;
RA   Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L.,
RA   Wright G., Shaffer A.L. III, Hodson D.J., Buras E., Liu X.-L., Powell J.I.,
RA   Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.M.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W.,
RA   Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.;
RT   "Burkitt lymphoma pathogenesis and therapeutic targets from structural
RT   and functional genomics.";
RL   Nature 490:116-120(2012).
//
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Murga Penas E.-M., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//